Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Core Insights - Immutep Limited has announced favorable initial safety data for IMP761, the world's first LAG-3 agonist, with no treatment-related adverse events reported in the first three cohorts of a Phase I study [1][2] - The study aims to assess the safety and immunosuppressive efficacy of IMP761 in healthy participants, with additional safety data and pharmacokinetic/pharmacodynamic assessments expected in the first half of CY2025 [2][3] Company Overview - Immutep is a clinical-stage biotechnology company focused on developing LAG-3 immunotherapies for cancer and autoimmune diseases, leveraging its expertise in LAG-3 to create innovative treatment options [6] - The company is conducting a Phase I trial of IMP761 at the Centre for Human Drug Research in the Netherlands, involving up to 49 participants [2] Product Details - IMP761 is designed to enhance the "brake" function of LAG-3 on T cells, aiming to restore immune system balance and address the root causes of various autoimmune diseases [1][3] - Preclinical studies have shown that IMP761 significantly decreases inflammatory cytokines and effectively suppresses antigen-specific T cell-mediated immune responses [3][5] Future Developments - The company is eager to generate more data from the ongoing study, which is crucial for derisking this promising asset in the context of autoimmune diseases [2] - Additional safety data and assessments of pharmacokinetic and pharmacodynamic relationships are anticipated in the first half of CY2025 [1][2]